<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">88345</article-id><article-id pub-id-type="doi">10.7554/eLife.88345</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>An in silico FSHD muscle fibre for modelling DUX4 dynamics and predicting the impact of therapy</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-314265"><name><surname>Cowley</surname><given-names>Matthew V</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5258-8024</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-314266"><name><surname>Pruller</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195279"><name><surname>Ganassi</surname><given-names>Massimo</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3163-9707</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-29085"><name><surname>Zammit</surname><given-names>Peter S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9562-3072</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-314267"><name><surname>Banerji</surname><given-names>Christopher RS</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4373-7657</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Chemistry</institution>, <institution>University of Bath</institution>, <addr-line><named-content content-type="city">Bath</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Randall Centre for Cell and Molecular Biophysics</institution>, <institution>King's College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution>The Alan Turing Institute</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-23994"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Reviewing editor</role><aff><institution>Seoul National University</institution>, <country>Republic of Korea</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>cbanerji@turing.ac.uk</email> (CB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>05</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e88345</elocation-id><history><date date-type="received"><day>13</day><month>04</month><year>2023</year></date><date date-type="accepted"><day>14</day><month>05</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Cowley et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Cowley et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-88345-v1.pdf"/><abstract><p>Facioscapulohumeral muscular dystrophy (FSHD) is an incurable myopathy linked to over-expression of the myotoxic transcription factor DUX4. Targeting DUX4 is the leading therapeutic approach, however it is only detectable in 0.1-3.8% of FSHD myonuclei. How rare DUX4 drives FSHD and the optimal anti-DUX4 strategy is unclear. We combine stochastic gene expression with compartment models of cell states, building a simulation of DUX4 expression and consequences in FSHD muscle fibres. Investigating iDUX4 myoblasts, scRNAseq and snRNAseq of FSHD muscle we estimate parameters including DUX4 mRNA degradation, transcription and translation rates and DUX4 target gene activation rates. Our model accurately recreates the distribution of DUX4 and target gene positive cells seen in scRNAseq of FSHD myocytes. Importantly we show DUX4 drives significant cell death despite expression in only 0.8% of live cells. Comparing scRNAseq of unfused FSHD myocytes to snRNAseq of fused FSHD myonuclei, we find evidence of DUX4 protein syncytial diffusion and estimate its rate via genetic algorithms. We package our model into freely available tools, to rapidly investigate consequences of anti-DUX4 therapy.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>EPSRC Centre for Doctoral Training in Sustainable Chemical Technologies</institution></institution-wrap></funding-source><award-id>EP/L016354/1</award-id><principal-award-recipient><name><surname>Cowley</surname><given-names>Matthew V</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012644</institution-id><institution>Friends of FSH Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Cowley</surname><given-names>Matthew V</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011724</institution-id><institution>Muscular Dystrophy UK</institution></institution-wrap></funding-source><award-id>19GRO-PG12-0493</award-id><principal-award-recipient><name><surname>Pruller</surname><given-names>Johanna</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>FSHD Society</institution></institution-wrap></funding-source><award-id>FSHD-Winter2021-4491649104</award-id><principal-award-recipient><name><surname>Pruller</surname><given-names>Johanna</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/S002472/1</award-id><principal-award-recipient><name><surname>Ganassi</surname><given-names>Massimo</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Association Francaise contre les Myopathies</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Zammit</surname><given-names>Peter S</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>SOLVE FSHD</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ganassi</surname><given-names>Massimo</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are publicly available or included in the manuscript, all code employed is published as part of our shiny app at 3 public domain URLs listed in the manuscript.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>van den Heuvel A</collab><collab>Mahfouz A</collab><collab>Kloet SL</collab><collab>Balog J</collab><collab>van Engelen BGM</collab><collab>Tawil R</collab><collab>Tapscott SJ</collab><collab>van der Maarel SM</collab></person-group><year iso-8601-date="2018">2018</year><source>facioscapulohumeral muscular dystrophy</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122873">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122873</ext-link><comment>NCBI Gene Expression Omnibus GSE122873</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Jiang S</collab><collab>Williams K</collab><collab>Kong X</collab><collab>Zeng W</collab><collab>Nguyen NV</collab><collab>Ma X</collab><collab>Tawil R</collab><collab>Yokomori K</collab><collab>Mortazavi A</collab></person-group><year iso-8601-date="2020">2020</year><source>Single-nucleus RNA-seq identifies divergent populations of FSHD2 myotube nucle</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143492">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143492</ext-link><comment>NCBI Gene Expression Omnibus GSE143492</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-88345-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>